Flatiron’s integrated real-world evidence solutions transform the possibilities of oncology research, development, and commercialization. Whether you're tackling bold research questions or time-critical decision points along the way, our solutions deliver the data, tools, and support you need to achieve your goals faster and more efficiently than ever before.
Solutions across the oncology product lifecycle
Flatiron’s tailored real-world evidence solutions can shorten timelines, minimize risks associated with drug development, and support access to the therapies that patients need. That’s why the world’s top life sciences companies rely on our solutions across the drug lifecycle, from research and development to in-market strategies.
Pioneering real-world data paired with the top real-world evidence experts
Flatiron employs a world-class oncology team, including clinical and research oncologists, biostatisticians, epidemiologists, and health outcomes researchers. With their dedication to high-quality real-world evidence, our real-world data is recognized as the best option for creating insights and evidence that power the future of cancer care.
From the point of care to insights and evidence
At Flatiron, we are integrated at the source. Thousands of community oncologists and academic centers nationwide use our technology and electronic health record systems, providing access to point of care data with traceability to source documents. But our commitment to data quality doesn't stop there. Our team of clinicians and data experts employ innovative and rigorous curation methods, including machine learning and data abstraction, to ensure the highest quality standards at the scale you require.
USE CASES
Learn how our customers are using Flatiron real-world evidence in oncology
Flatiron’s oncology real-world evidence solutions accelerate drug discovery by bridging the gap between genomics and clinical outcomes. Access to data on biomarkers, clinical characteristics, and outcomes improves the likelihood that you’ll discover the right drug targets in the right patient populations. Flatiron’s robust and trusted real-world data are available for specific cancer types, including rare diseases, or across multiple tumors.
When the stakes are high, our biopharma partners use Flatiron’s oncology real-world evidence solutions, including fast insights, to support quick and impactful business decisions. Flatiron’s solutions can help you identify gaps and opportunities in your portfolio by gaining a deep understanding of the cancer landscape, in totality and by disease.
Flatiron’s oncology real-world evidence solutions accelerate and enhance clinical trial design, execution, and interpretation of results. Our industry experts and fit-for-purpose data improve your chances of generating the right RWE to support drug approval while maximizing efficiencies and cost-savings.
Submit your application with confidence when it matters the most by working with Flatiron. Our real-world data follows the highest regulatory-grade quality standards, and we have a long track record of partnering with leading biopharma companies to produce real-world evidence packages submitted to regulators in the U.S., Europe, and Asia.
As a pioneer in this space, Flatiron has partnered with the FDA, Duke-Margolis Health Policy Center, and others to advance data auditability, data depth, and endpoint validation.
Demonstrate your cancer drug’s value to payers and Health Technology Assessment (HTA) bodies with Flatiron’s oncology real-world evidence. Flatiron has both the expertise and the comprehensive data you need—whether evaluating health outcomes in specific patient cohorts or understanding treatment sequencing and testing patterns across tumor types.
Our extensive experience in HEOR and comparative effectiveness studies helps equip payers with the real-world evidence they need to make the best decisions, accelerating access to life-extending cancer treatments worldwide.
Flatiron has advanced the science of real-world evidence with key partners
